Jiangsu Simcere’s Edaravone, Borneol Sublingual Tablet Earns FDA Breakthrough Therapy Designation for Stroke Treatment
HONG KONG—Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received Breakthrough...
Jiangsu Simcere Acquires Exclusive Rights to TargetRx’s TGRX-326 in Licensing Deal
SHENZHEN—Shenzhen TargetRx, Inc., a leading developer of small-molecule kinase inhibitors, has entered into a licensing...
GeneQuantum Healthcare’s GQ1005 ADC Receives CDE Clearance for Phase III Breast Cancer Trial
SUZHOU—GeneQuantum Healthcare (Suzhou) Co., Ltd has received clearance from the Center for Drug Evaluation (CDE)...
Beijing Balance Medical Secures NMPA Nod for Renatus Transcatheter Aortic Valve System
BEIJING—Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has received market approval from the National...
Sinocelltech’s Anti-Angiogenic Biologic SCT520FF Gets NMPA Green Light for Neovascular AMD Clinical Study
SHANGHAI—Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that it has received...
Zhejiang Dian Diagnostics Partners with Shanghai Mycology Lab to Advance Fungal Infection Diagnostics
SHANGHAI—Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading player in the diagnostics industry, has...
Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...
China’s Evopoint Biosciences and UK’s GSK Eye Breakthrough Therapy Designations for Cancer Therapies
BEIJING/LONDON—The Center for Drug Evaluation (CDE) in China has indicated that Evopoint Biosciences’ EZH2 inhibitor...
Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials
HONG KONG—Duality Biologics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is...
MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1
SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...
Shandong Buchang Pharmaceuticals’ rhEPO-Fc for CKD Anemia Accepted for Review by China’s CDE
BEIJING—The Center for Drug Evaluation (CDE) in China has accepted the market filing for a...
Biocon Biologics Resolves Patent Dispute with J&J, Secures Market Entry for Biosimilar Stelara
Biocon Biologics Ltd, the biosimilars division of Indian pharmaceutical company Biocon Ltd (BOM: 532523, NSE:...
Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan
Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US...
HutchMed Halts China Filing for Gastric Cancer Drug Fruquintinib Following Regulatory Feedback
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013), a China-based biopharmaceutical company, has announced the withdrawal...
Novo Nordisk to Resubmit Wegovy Heart Failure Application with Updated Clinical Data
Denmark’s pharmaceutical giant, Novo Nordisk (NYSE: NVO), has reported significant findings on the efficacy of...
AccurEdit Therapeutics’ Gene-Editing Drug ART001 Clears FDA Hurdle for US Clinical Trials
SUZHOU—AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading Chinese specialist in gene editing therapies, has announced...
Hybio Pharmaceutical Inks Licensing Deal with Mullan Pharmaceutical for Liraglutide Biosimilar
BEIJING—Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese biopharmaceutical company, has entered into a licensing...
Allist Pharmaceuticals Acquires Jacobio’s G12C Inhibitor and SHP2 Inhibitor Rights for Greater China Region
SHANGHAI—Allist Pharmaceuticals Co., Ltd, a Shanghai-based biotech company, has entered into a licensing agreement with...
Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital
BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into...
Bio-Thera Solutions’ BAT2406 Biosimilar Gets Green Light for Clinical Trials in China
GUANGZHOU—Bio-Thera Solutions (SHA: 688177), a leading biopharmaceutical company based in Guangzhou, has received approval from...